Added to YB: 2024-02-09
Pitch date: 2024-02-08
TGTX [bullish]
TG Therapeutics, Inc.
+164.6%
current return
Author Info
No bio for this author
Company Info
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Market Cap
$6.0B
Pitch Price
$14.83
Price Target
24.00 (-39%)
Dividend
N/A
EV/EBITDA
41.48
P/E
14.86
EV/Sales
8.97
Sector
Biotechnology
Category
growth
TG Therapeutics: Inferred Expectations Point To Undervalued Shares
$TGTX: BRIUMVI MS drug launch strong w/ $89M sales, aims for $1B+ of $30B market. Bullish PT $24 (base) to $60 (bull), 50%+ upside. Risks: competition, execution, funding needs. Well positioned in $10B+ growing CD20 mAb class; attractive M&A target.
Read full article (13 min)